Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense

Molecular Therapy

Volumn 19, Issue 12, 2011, Pages 2163-2168

  Moschos, Sterghios A ^a,b   Frick, Manfred ^a,c   Taylor, Bruce ^a   Turnpenny, Paul ^a   Graves, Helen ^a   Spink, Karen G ^a   Brady, Kevin ^a   Lamb, David ^a   Collins, David ^a   Rockel, Thomas D ^d   Weber, Markus ^d   Lazari, Ovadia ^a   Perez Tosar, Luis ^a   Fancy, Sally A ^a   Lapthorn, Chris ^a   Green, Martin X ^a   Evans, Steve ^a   Selby, Matthew ^a   Jones, Gareth ^a   Jones, Lyn ^a   Kearney, Sarah ^a   Mechiche, Houria ^a   Gikunju, Diana ^e   Subramanian, Romesh ^e   Uhlmann, Eugen ^d   Jurk, Marion ^d   Vollmer, Jörg ^d   Ciaramella, Giuseppe ^a   Yeadon, Michael ^a   more..

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b UNIVERSITY OF WESTMINSTER   (United Kingdom)

^c UNIVERSITY OF ULM   (Germany)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FLUORESCENT DYE; LOCKED NUCLEIC ACID; OLIGONUCLEOTIDE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SELECTION; CELL TYPE; CHEMICAL LABELING; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; DRUG UPTAKE; GENE SILENCING; KIDNEY; LIVER; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; MALE; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS;

ANIMALIA; MUS;

EID: 82955233645     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.206     Document Type: Article

References (29)

1. Moschos, SA, Spinks, K, Williams, AE and Lindsay, MA (2008). Targeting the lung using siRNA and antisense based oligonucleotides. Curr Pharm Des 14:3620-3627.
2. Barnes, PJ (2008). The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 118:3546-3556.
3. Gauvreau, GM, Boulet, L P, Cockcroft, DW, Baatjes, A, Cote, J, Deschesnes, F et al. (2008). Antisense therapy against CCR3 and the common β chain attenuates allergeninduced eosinophilic responses. Am J Respir Crit Care Med 177:952-958. (Pubitemid 351717588)
4. Alvarez, R, Elbashir, S, Borland, T, Toudjarska, I, Hadwiger, P, John, M et al. (2009). RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 53:3952-3962.
5. Vaishnaw, AK, Gollob, J, Gamba-Vitalo, C, Hutabarat, R, Sah, D, Meyers, R et al. (2010). A status report on RNAi therapeutics. Silence 1:14.
6. Weers, JG, Bell, J, Chan, HK, Cipolla, D, Dunbar, C, Hickey, AJ et al. (2010). Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv 23 Suppl 2:S5-23.
7. Roy, I and Vij, N (2010). Nanodelivery in airway diseases: challenges and therapeutic applications. Nanomedicine 6:237-244.
8. Ponnappa, BC (2009). siRNA for inflammatory diseases. Curr Opin Investig Drugs 10:418-424.
9. Lam, JK, Liang, W and Chan, HK (2011). Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev (epub ahead of print).
10. Straarup, EM, Fisker, N, Hedtjärn, M, Lindholm, MW, Rosenbohm, C, Aarup, V et al. (2010). Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res 38:7100-7111.
11. Kurreck, J, Wyszko, E, Gillen, C and Erdmann, VA (2002). Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 30:1911-1918. (Pubitemid 34537585)
12. Obad, S, dos Santos, CO, Petri, A, Heidenblad, M, Broom, O, Ruse, C et al. (2011). Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43:371-378.
13. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173-178. (Pubitemid 39545841)
14. Stein, CA, Hansen, JB, Lai, J, Wu, S, Voskresenskiy, A, Høg, A et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 38:e3.
15. Zhang, Y, Qu, Z, Kim, S, Shi, V, Liao, B, Kraft, P et al. (2011). Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther 18:326-333.
16. Zheng, BJ, Guan, Y, Tang, Q, Du, C, Xie, FY, He, ML et al. (2004). Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir Ther (Lond) 9:365-374. (Pubitemid 38878752)
17. Collinet, C, Stöter, M, Bradshaw, CR, Samusik, N, Rink, JC, Kenski, D et al. (2010). Systems survey of endocytosis by multiparametric image analysis. Nature 464:243-249.
18. Donaldson, JG, Porat-Shliom, N and Cohen, LA (2009). Clathrin-independent endocytosis: a unique platform for cell signaling and PM remodeling. Cell Signal 21:1-6.
19. Pelkmans, L, Bürli, T, Zerial, M and Helenius, A (2004). Caveolin-stabilized membrane domains as multifunctional transport and sorting devices in endocytic membrane traffic. Cell 118:767-780. (Pubitemid 39221735)
20. Sandvig, K, Torgersen, ML, Raa, HA and van Deurs, B (2008). Clathrin-independent endocytosis: from nonexisting to an extreme degree of complexity. Histochem Cell Biol 129:267-276.
21. Nicklin, PL, Bayley, D, Giddings, J, Craig, SJ, Cummins, LL, Hastewell, JG et al. (1998). Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes. Pharm Res 15:583-591. (Pubitemid 28214952)
22. Griesenbach, U, Kitson, C, Escudero Garcia, S, Farley, R, Singh, C, Somerton, L et al. (2006). Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo. Respir Res 7:26.
23. Glud, SZ, Bramsen, JB, Dagnaes-Hansen, F, Wengel, J, Howard, KA, Nyengaard, JR et al. (2009). Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. Oligonucleotides 19:163-168.
24. Kleinman, ME, Yamada, K, Takeda, A, Chandrasekaran, V, Nozaki, M, Baffi, JZ et al. (2008). Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591-597. (Pubitemid 351483358)
25. Robbins, M, Judge, A, Ambegia, E, Choi, C, Yaworski, E, Palmer, L et al. (2008). Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 19:991-999.
26. Ripple, MJ, You, D, Honnegowda, S, Giaimo, JD, Sewell, AB, Becnel, DM et al. (2010). Immunomodulation with IL-4Rα antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease. J Immunol 185:4804-4811.
27. Tian, XR, Tian, XL, Bo, J P, Li, SG, Liu, ZL and Niu, B (2011). Inhibition of allergic airway inflammation by antisense-induced blockade of STAT6 expression. Chin Med J 124:26-31.
28. Ignowski, JM and Schaffer, DV (2004). Kinetic analysis and modeling of frefy luciferase as a quantitative reporter gene in live mammalian cells. Biotechnol Bioeng 86:827-834. (Pubitemid 38745701)
29. Brandes, C, Plautz, JD, Stanewsky, R, Jamison, CF, Straume, M, Wood, KV et al. (1996). Novel features of drosophila period Transcription revealed by real-time luciferase reporting. Neuron 16:687-692. (Pubitemid 26124045)